3D spatial biology company Alpenglow Biosciences and MRI-based AI developer Virdx have entered a strategic agreement focused on prostate cancer diagnostics.
Under the multiyear collaboration, Alpenglow will generate a comprehensive 3D dataset using light-sheet microscopy to image full cross-sections of human prostate tissue. This dataset will serve as a high-resolution ground truth to enhance the performance of Virdx’s MRI-based AI algorithm for diagnosing prostate cancer, Alpenglow said.
The agreement highlights the value of ground truth data for AI-based clinical tools and illustrates efforts to bridge 3D pathology with volumetric imaging, the company added.
